This research investigates the efficacy and safety of Nicotinamide Mononucleotide (NMN) supplementation in healthy middle-aged adults.
The study, a randomized, multicenter, double-blind, placebo-controlled clinical trial, specifically examines how NMN impacts blood NAD concentration, physical performance, biological age, insulin sensitivity, and overall health over a 60-day period. Researchers administered daily oral doses of 300 mg, 600 mg, or 900 mg of NMN, comparing the results against a placebo group.
The findings suggest that NMN significantly increases NAD levels and positively influences physical endurance and general health, with a 600 mg dose appearing to achieve maximum efficacy without additional benefits from a higher 900 mg dose, and importantly, no safety concerns were identified within the trial.
Pure, targeted CMS-121 molecule designed to provide deep support for the brain, mitochondria, and cognitive resilience.
As the science of longevity and metabolic health evolves, few molecules have garnered as much attention as nicotinamide adenine dinucleotide (NAD⁺). Widely recognized as a coenzyme crucial for energy metabolism, DNA repair, and cell survival, NAD⁺ levels naturally...
As global life expectancy increases, so does the demand for strategies to maintain cognitive health. From aging populations to young professionals seeking mental clarity, brain performance is becoming the next frontier of functional nutrition
Nicotinamide mononucleotide (NMN) has gained global attention as a powerful NAD⁺ precursor with potential to combat aging and boost cellular health. But beyond longevity hype, what does the science really say—especially about its effects on the digestive system?
Can a molecule inspired by strawberries help fight one of the most complex diseases of our time? CMS-121, a refined derivative of fisetin, shows promising neuroprotective effects in preclinical models of Alzheimer’s.
